About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 73976, 17 pages
http://dx.doi.org/10.1155/JBB/2006/73976
Review Article

Roles of Cholesterol and Lipids in the Etiopathogenesis of Alzheimer's Disease

1Laboratory of Cellular and Molecular Biology and Neurosciences, Millennium Institute for Advanced Studies in Cell Biology and Biotechnology (CBB), Millennium Building, Las Encinas 3370, Ñuñoa, Santiago, Chile
2Department of Chemistry, Arturo Prat University, avenue Arturo Prat 2120, Iquique, Chile
3Department of Neurological Sciences, Faculty of Medicine, University of Chile, Salvador 486, Providencia, Santiago 750-0922, Chile

Received 2 December 2005; Revised 25 May 2006; Accepted 30 May 2006

Copyright © 2006 Leonel Rojo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J Abad-Rodriguez, M D Ledesma, K Craessaerts, et al., “Neuronal membrane cholesterol loss enhances amyloid peptide generation,” Journal of Cell Biology, vol. 167, no. 5, pp. 953–960, 2004. View at Publisher · View at Google Scholar
  2. H Akiyama and P L McGeer, “Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease,” Nature Medicine, vol. 10, no. 2, pp. 117–118, 2004. View at Publisher · View at Google Scholar
  3. A Aliyev, S G Chen, D Seyidova, et al., “Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease,” Journal of the Neurological Sciences, vol. 229-230, pp. 285–292, 2005. View at Publisher · View at Google Scholar
  4. A Alvarez, J P Muñoz, and R B Maccioni, “A cdk5-p35 stable complex is involved in the β-amyloid-induced deregulation of cdk5 activity in hippocampal neurons,” Experimental Cell Research, vol. 264, no. 2, pp. 266–274, 2001. View at Publisher · View at Google Scholar
  5. R GW Anderson and K Jacobson, “A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains,” Science, vol. 296, no. 5574, pp. 1821–1825, 2002. View at Publisher · View at Google Scholar
  6. A Andreadis, “Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1739, no. 2, pp. 91–103, 2005. View at Publisher · View at Google Scholar
  7. J Armstrong, M Boada, M J Rey, N Vidal, and I Ferrer, “Familial Alzheimer disease associated with A713T mutation in APP,” Neuroscience Letters, vol. 370, no. 2-3, pp. 241–243, 2004. View at Publisher · View at Google Scholar
  8. D N Arvanitis, W Min, Y Gong, Y M Heng, and J M Boggs, “Two types of detergent-insoluble, glycosphingolipid/cholesterol-rich membrane domains from isolated myelin,” Journal of Neurochemistry, vol. 94, no. 6, pp. 1696–1710, 2005. View at Publisher · View at Google Scholar
  9. J C Augustinack, A Schneider, E-M Mandelkow, and B T Hyman, “Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease,” Acta Neuropathologica, vol. 103, no. 1, pp. 26–35, 2002. View at Publisher · View at Google Scholar
  10. P Banerjee, J B Joo, J T Buse, and G Dawson, “Differential solubilization of lipids along with membrane proteins by different classes of detergents,” Chemistry and Physics of Lipids, vol. 77, no. 1, pp. 65–78, 1995. View at Publisher · View at Google Scholar
  11. M F Beal, “Mitochondria, oxidative damage, and inflammation in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 120–131, 2003.
  12. K Bhaskar, S-H Yen, and G Lee, “Disease-related modifications in tau affect the interaction between Fyn and tau,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35119–35125, 2005. View at Publisher · View at Google Scholar
  13. J Biernat, N Gustke, G Drewes, E-M Mandelkow, and E Mandelkow, “Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding,” Neuron, vol. 11, no. 1, pp. 153–163, 1993. View at Publisher · View at Google Scholar
  14. M L Billingsley and R L Kincaid, “Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration,” Biochemical Journal, vol. 323, no. 3, pp. 577–591, 1997.
  15. L I Binder, A L Guillozet-Bongaarts, F Garcia-Sierra, and R W Berry, “Tau, tangles, and Alzheimer's disease,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1739, no. 2, pp. 216–223, 2005. View at Publisher · View at Google Scholar
  16. J Blonder, A Terunuma, T P Conrads, et al., “A proteomic characterization of the plasma membrane of human epidermis by high-throughput mass spectrometry,” Journal of Investigative Dermatology, vol. 123, no. 4, pp. 691–699, 2004. View at Publisher · View at Google Scholar
  17. I Bourdel-Marchasson, M-C Delmas-Beauvieux, E Peuchant, et al., “Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients,” Age and Ageing, vol. 30, no. 3, pp. 235–241, 2001. View at Publisher · View at Google Scholar
  18. R Brandt and G Lee, “Orientation, assembly, and stability of microtubule bundles induced by a fragment of tau protein,” Cell Motility and the Cytoskeleton, vol. 28, no. 2, pp. 143–154, 1994. View at Publisher · View at Google Scholar
  19. D Brigger and T J Muckle, “Comparison of Sirius red and Congo red as stains for amyloid in animal tissues,” Journal of Histochemistry and Cytochemistry, vol. 23, no. 1, pp. 84–88, 1975.
  20. D A Brown, “Seeing is believing: visualization of rafts in model membranes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10517–10518, 2001. View at Publisher · View at Google Scholar
  21. D A Brown and E London, “Structure and function of sphingolipid- and cholesterol-rich membrane rafts,” Journal of Biological Chemistry, vol. 275, no. 23, pp. 17221–17224, 2000. View at Publisher · View at Google Scholar
  22. V Buée-Scherrer and M Goedert, “Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells,” FEBS Letters, vol. 515, no. 1–3, pp. 151–154, 2002. View at Publisher · View at Google Scholar
  23. D A Butterfield and C B Pocernich, “The glutamatergic system and Alzheimer's disease: therapeutic implications,” CNS Drugs, vol. 17, no. 9, pp. 641–652, 2003. View at Publisher · View at Google Scholar
  24. J D Buxbaum, E I Cullen, and L T Friedhoff, “Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients,” Frontiers in Bioscience, vol. 7, pp. a50–a59, 2002.
  25. H Cheng, J Xu, D W Jr McKeel, and X Han, “Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study,” Cellular and Molecular Biology, vol. 49, no. 5, pp. 809–818, 2003.
  26. M Citron, “Alzheimer's disease: treatments in discovery and development,” Nature Neuroscience, vol. 5, no. suppl, pp. 1055–1057, 2002. View at Publisher · View at Google Scholar
  27. M Citron, “β-Secretase inhibition for the treatment of Alzheimer's disease—promise and challenge,” Trends in Pharmacological Sciences, vol. 25, no. 2, pp. 92–97, 2004. View at Publisher · View at Google Scholar
  28. E H Corder, A M Saunders, W J Strittmatter, et al., “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families,” Science, vol. 261, no. 5123, pp. 921–923, 1993. View at Publisher · View at Google Scholar
  29. A Cordle, J Koenigsknecht-Talboo, B Wilkinson, A Limpert, and G Landreth, “Mechanisms of statin-mediated inhibition of small G-protein function,” Journal of Biological Chemistry, vol. 280, no. 40, pp. 34202–34209, 2005. View at Publisher · View at Google Scholar
  30. A Cordle, J Koenigsknecht-Talboo, B Wilkinson, A Limpert, and G Landreth, “Mechanisms of statin-mediated inhibition of small G-protein function,” Journal of Biological Chemistry, vol. 280, no. 40, pp. 34202–34209, 2005. View at Publisher · View at Google Scholar
  31. A Cordle and G Landreth, “3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses,” Journal of Neuroscience, vol. 25, no. 2, pp. 299–307, 2005. View at Publisher · View at Google Scholar
  32. A Cordle and G Landreth, “3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses,” Journal of Neuroscience, vol. 25, no. 2, pp. 299–307, 2005. View at Publisher · View at Google Scholar
  33. P E Coskun, M F Beal, and D C Wallace, “Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10726–10731, 2004. View at Publisher · View at Google Scholar
  34. J L Cummings and G Cole, “Alzheimer disease,” Journal of the American Medical Association, vol. 287, no. 18, pp. 2335–2338, 2002. View at Publisher · View at Google Scholar
  35. R E Davis, S Miller, C Herrnstadt, et al., “Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4526–4531, 1997. View at Publisher · View at Google Scholar
  36. P Derkinderen, T M.E Scales, D P Hanger, et al., “Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase,” Journal of Neuroscience, vol. 25, no. 28, pp. 6584–6593, 2005. View at Publisher · View at Google Scholar
  37. L Désiré, J Bourdin, N Loiseau, et al., “RAC1 inhibition targets amyloid precursor protein processing by γ-secretase and decreases Aβ production in vitro and in vivo,” Journal of Biological Chemistry, vol. 280, no. 45, pp. 37516–37525, 2005. View at Publisher · View at Google Scholar
  38. J M Dietschy and S D Turley, “Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal,” Journal of Lipid Research, vol. 45, no. 8, pp. 1375–1397, 2004. View at Publisher · View at Google Scholar
  39. M Edidin, “The state of lipid rafts: from model membranes to cells,” Annual Review of Biophysics and Biomolecular Structure, vol. 32, pp. 257–283, 2003. View at Publisher · View at Google Scholar
  40. R Ehehalt, P Keller, C Haass, C Thiele, and K Simons, “Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts,” Journal of Cell Biology, vol. 160, no. 1, pp. 113–123, 2003. View at Publisher · View at Google Scholar
  41. J M Ellis, “Cholinesterase inhibitors in the treatment of dementia,” Journal of the American Osteopathic Association, vol. 105, no. 3, pp. 145–158, 2005.
  42. R M Evans, S Hui, A Perkins, D K Lahiri, J Poirier, and M R Farlow, “Cholesterol and APOE genotype interact to influence Alzheimer disease progression,” Neurology, vol. 62, no. 10, pp. 1869–1871, 2004.
  43. M Ezquerra, A Lleó, M Castellví, et al., “A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease,” Archives of Neurology, vol. 60, no. 8, pp. 1149–1151, 2003. View at Publisher · View at Google Scholar
  44. L A Farrer, L A Cupples, J L Haines, et al., “Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis,” Journal of the American Medical Association, vol. 278, no. 16, pp. 1349–1356, 1997. View at Publisher · View at Google Scholar
  45. A M Gallegos, A L McIntosh, B P Atshaves, and F Schroeder, “Structure and cholesterol domain dynamics of an enriched caveolae/raft isolate,” Biochemical Journal, vol. 382, no. 2, pp. 451–461, 2004. View at Publisher · View at Google Scholar
  46. S Gao, H C Hendrie, K S Hall, and S Hui, “The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis,” Archives of General Psychiatry, vol. 55, no. 9, pp. 809–815, 1998. View at Publisher · View at Google Scholar
  47. S G Gauthier, “Alzheimer's disease: the benefits of early treatment,” European Journal of Neurology, vol. 12, no. suppl 3, pp. 11–16, 2005. View at Publisher · View at Google Scholar
  48. A J George, R MD Holsinger, C A McLean, et al., “APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease,” Neurobiology of Disease, vol. 16, no. 1, pp. 124–132, 2004. View at Publisher · View at Google Scholar
  49. F G Gervais, D Xu, G S Robertson, et al., “Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation,” Cell, vol. 97, no. 3, pp. 395–406, 1999. View at Publisher · View at Google Scholar
  50. G G Glenner and C W Wong, “Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein,” Biochemical and Biophysical Research Communications, vol. 122, no. 3, pp. 1131–1135, 1984. View at Publisher · View at Google Scholar
  51. R Godemann, J Biernat, E Mandelkow, and E-M Mandelkow, “Phosphorylation of tau protein by recombinant GSK-3β: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain,” FEBS Letters, vol. 454, no. 1-2, pp. 157–164, 1999. View at Publisher · View at Google Scholar
  52. O Grip, S Janciauskiene, and S Lindgren, “Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes,” Inflammation Research, vol. 51, no. 2, pp. 58–62, 2002.
  53. H Grossman, “Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease,” CNS Spectrums, vol. 8, no. 11, pp. 815–823, 2003.
  54. X Han, A M Fagan, H Cheng, J C Morris, C Xiong, and D M Holtzman, “Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia,” Annals of Neurology, vol. 54, no. 1, pp. 115–119, 2003. View at Publisher · View at Google Scholar
  55. T Harder and K Simons, “Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains,” Current Opinion in Cell Biology, vol. 9, no. 4, pp. 534–542, 1997. View at Publisher · View at Google Scholar
  56. R D Harry and K K Zakzanis, “A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis,” Human Psychopharmacology, vol. 20, no. 3, pp. 183–187, 2005. View at Publisher · View at Google Scholar
  57. K Höglund, K M Thelen, S Syversen, et al., “The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 19, no. 5-6, pp. 256–265, 2005. View at Publisher · View at Google Scholar
  58. W G Honer, “Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals,” Neurobiology of Aging, vol. 24, no. 8, pp. 1047–1062, 2003. View at Publisher · View at Google Scholar
  59. C Hope, J Mettenburg, S L Gonias, S T DeKosky, M I Kamboh, and C T Chu, “Functional analysis of plasma α2-macroglobulin from Alzheimer's disease patients with the A2M intronic deletion,” Neurobiology of Disease, vol. 14, no. 3, pp. 504–512, 2003. View at Publisher · View at Google Scholar
  60. T Hutchin and G Cortopassi, “A mitochondrial DNA clone is associated with increased risk for Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 15, pp. 6892–6895, 1995. View at Publisher · View at Google Scholar
  61. J H Ipsen, G Karlström, O G Mouritsen, H Wennerström, and M J Zuckermann, “Phase equilibria in the phosphatidylcholine-cholesterol system,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 905, no. 1, pp. 162–172, 1987.
  62. S Ishibashi, J Herz, N Maeda, J L Goldstein, and M S Brown, “The two-receptor model of lipoprotein clearance: tests of the hypothesis in “knockout” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 10, pp. 4431–4435, 1994. View at Publisher · View at Google Scholar
  63. A Ishikawa, Y-S Piao, A Miyashita, et al., “A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease,” Annals of Neurology, vol. 57, no. 3, pp. 429–434, 2005. View at Publisher · View at Google Scholar
  64. G P Jarvik, E M Wijsman, W A Kukull, G D Schellenberg, C Yu, and E B Larson, “Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study,” Neurology, vol. 45, no. 6, pp. 1092–1096, 1995.
  65. H Jick, G L Zornberg, S S Jick, S Seshadri, and D A Drachman, “Statins and the risk of dementia,” Lancet, vol. 356, no. 9242, pp. 1627–1631, 2000. View at Publisher · View at Google Scholar
  66. H Kaduszkiewicz, T Zimmermann, H-P Beck-Bornholdt, and H van den Bussche, “Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials,” British Medical Journal, vol. 331, no. 7512, pp. 321–323, 2005. View at Publisher · View at Google Scholar
  67. N Kahya, E-I Pécheur, W P de Boeij, D A Wiersma, and D Hoekstra, “Reconstitution of membrane proteins into giant unilamellar vesicles via peptide-induced fusion,” Biophysical Journal, vol. 81, no. 3, pp. 1464–1474, 2001.
  68. N Kahya, D Scherfeld, K Bacia, B Poolman, and P Schwille, “Probing lipid mobility of raft-exhibiting model membranes by fluorescence correlation spectroscopy,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 28109–28115, 2003. View at Publisher · View at Google Scholar
  69. N Kahya, D Scherfeld, K Bacia, and P Schwille, “Lipid domain formation and dynamics in giant unilamellar vesicles explored by fluorescence correlation spectroscopy,” Journal of Structural Biology, vol. 147, no. 1, pp. 77–89, 2004. View at Publisher · View at Google Scholar
  70. L Kalvodova, N Kahya, P Schwille, et al., “Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro,” Journal of Biological Chemistry, vol. 280, no. 44, pp. 36815–36823, 2005. View at Publisher · View at Google Scholar
  71. L Kalvodova, N Kahya, P Schwille, et al., “Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro,” Journal of Biological Chemistry, vol. 280, no. 44, pp. 36815–36823, 2005. View at Publisher · View at Google Scholar
  72. J Kang, H-G Lemaire, A Unterbeck, et al., “The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor,” Nature, vol. 325, no. 6106, pp. 733–736, 1987. View at Publisher · View at Google Scholar
  73. B L Kelly, R Vassar, and A Ferreira, “β-amyloid-induced dynamin 1 depletion in hippocampal neurons: a potential mechanism for early cognitive decline in Alzheimer disease,” Journal of Biological Chemistry, vol. 280, no. 36, pp. 31746–31753, 2005. View at Publisher · View at Google Scholar
  74. C Kirsch, G P Eckert, and W E Mueller, “Statin effects on cholesterol micro-domains in brain plasma membranes,” Biochemical Pharmacology, vol. 65, no. 5, pp. 843–856, 2003. View at Publisher · View at Google Scholar
  75. M Kivipelto, T Ngandu, L Fratiglioni, et al., “Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease,” Archives of Neurology, vol. 62, no. 10, pp. 1556–1560, 2005. View at Publisher · View at Google Scholar
  76. C Klein, E-M Krämer, A-M Cardine, B Schraven, R Brandt, and J Trotter, “Process outgrowth of oligodendrocytes is promoted by interaction of Fyn kinase with the cytoskeletal protein Tau,” Journal of Neuroscience, vol. 22, no. 3, pp. 698–707, 2002.
  77. W L Klein, W B Jr Stine, and D B Teplow, “Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 569–580, 2004. View at Publisher · View at Google Scholar
  78. A R Koudinov and T T Berezov, “Cholesterol, statins, and Alzheimer disease,” PLoS Medicine, vol. 2, no. 3, p. e81, 2005. View at Publisher · View at Google Scholar
  79. W A Kukull, R Higdon, J D Bowen, et al., “Dementia and Alzheimer disease incidence: a prospective cohort study,” Archives of Neurology, vol. 59, no. 11, pp. 1737–1746, 2002. View at Publisher · View at Google Scholar
  80. Y-M Kuo, M R Emmerling, C L Bisgaier, et al., “Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1–42 levels,” Biochemical and Biophysical Research Communications, vol. 252, no. 3, pp. 711–715, 1998. View at Publisher · View at Google Scholar
  81. D K Lahiri, “Advances in the four major pillars of Alzheimer's disease research: pathobiology, genetics, diagnosis, and treatment,” Current Alzheimer Research, vol. 1, no. 3, pp. i–ii, 2004.
  82. M Lavados, G Farías, F Rothhammer, et al., “ApoE alleles and tau markers in patients with different levels of cognitive impairment,” Archives of Medical Research, vol. 36, no. 5, pp. 474–479, 2005. View at Publisher · View at Google Scholar
  83. G Lee, “Tau and src family tyrosine kinases,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1739, no. 2, pp. 323–330, 2005. View at Publisher · View at Google Scholar
  84. G Lee, R Thangavel, V M Sharma, et al., “Phosphorylation of tau by fyn: implications for Alzheimer's disease,” Journal of Neuroscience, vol. 24, no. 9, pp. 2304–2312, 2004. View at Publisher · View at Google Scholar
  85. L Li, D Cao, D W Garber, H Kim, and K-I Fukuchi, “Association of aortic atherosclerosis with cerebral β-amyloidosis and learning deficits in a mouse model of Alzheimer's disease,” American Journal of Pathology, vol. 163, no. 6, pp. 2155–2164, 2003.
  86. L Li, D Cao, D W Garber, H Kim, and K-I Fukuchi, “Association of aortic atherosclerosis with cerebral β-amyloidosis and learning deficits in a mouse model of Alzheimer's disease,” American Journal of Pathology, vol. 163, no. 6, pp. 2155–2164, 2003.
  87. J K Liao, “Isoprenoids as mediators of the biological effects of statins,” Journal of Clinical Investigation, vol. 110, no. 3, pp. 285–288, 2002. View at Publisher · View at Google Scholar
  88. J K Liao and U Laufs, “Pleiotropic effects of statins,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 89–118, 2005. View at Publisher · View at Google Scholar
  89. S Locatelli, D Lütjohann, H H-J Schmidt, C Otto, U Beisiegel, and K von Bergmann, “Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain,” Archives of Neurology, vol. 59, no. 2, pp. 213–216, 2002. View at Publisher · View at Google Scholar
  90. M A Lovell, C Xie, and W R Markesbery, “Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures,” Neurobiology of Aging, vol. 22, no. 2, pp. 187–194, 2001. View at Publisher · View at Google Scholar
  91. J A Luchsinger, C Reitz, L S Honig, M-X Tang, S Shea, and R Mayeux, “Aggregation of vascular risk factors and risk of incident Alzheimer disease,” Neurology, vol. 65, no. 4, pp. 545–551, 2005. View at Publisher · View at Google Scholar
  92. D Lütjohann, A Papassotiropoulos, I Björkhem, et al., “Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients,” Journal of Lipid Research, vol. 41, no. 2, pp. 195–198, 2000.
  93. T Maas, J Eidenmüller, and R Brandt, “Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 15733–15740, 2000. View at Publisher · View at Google Scholar
  94. R B Maccioni and V Cambiazo, “Role of microtubule-associated proteins in the control of microtubule assembly,” Physiological Reviews, vol. 75, no. 4, pp. 835–864, 1995.
  95. R B Maccioni, M Lavados, C B Maccioni, and A Mendoza-Naranjo, “Biological markers of Alzheimer's disease and mild cognitive impairment,” Current Alzheimer Research, vol. 1, no. 4, pp. 307–314, 2004. View at Publisher · View at Google Scholar
  96. R B Maccioni, J P Muñoz, and L Barbeito, “The molecular bases of Alzheimer's disease and other neurodegenerative disorders,” Archives of Medical Research, vol. 32, no. 5, pp. 367–381, 2001. View at Publisher · View at Google Scholar
  97. R B Maccioni, C Otth, I I Concha, and J P Muñoz, “The protein kinase cdk5: structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology,” European Journal of Biochemistry, vol. 268, no. 6, pp. 1518–1527, 2001. View at Publisher · View at Google Scholar
  98. E-M Mandelkow, J Biernat, G Drewes, N Gustke, B Trinczek, and E Mandelkow, “Tau domains, phosphorylation, and interactions with microtubules,” Neurobiology of Aging, vol. 16, no. 3, pp. 355–362, 1995. View at Publisher · View at Google Scholar
  99. E-M Mandelkow, E Thies, B Trinczek, J Biernat, and E Mandelkow, “MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons,” Journal of Cell Biology, vol. 167, no. 1, pp. 99–110, 2004. View at Publisher · View at Google Scholar
  100. L T McGrath, B M McGleenon, S Brennan, D McColl, S McIlroy, and A P Passmore, “Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde,” QJM, vol. 94, no. 9, pp. 485–490, 2001. View at Publisher · View at Google Scholar
  101. Megha and E London, “Ceramide selectively displaces cholesterol from ordered lipid domains (rafts),” Journal of Biological Chemistry, vol. 279, no. 11, pp. 9997–10004, 2004.
  102. C Merchant, M-X Tang, S Albert, J Manly, Y Stern, and R Mayeux, “The influence of smoking on the risk of Alzheimer's disease,” Neurology, vol. 52, no. 7, pp. 1408–1412, 1999.
  103. T J Montine, V Amarnath, M E Martin, W J Strittmatter, and D G Graham, “E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures,” American Journal of Pathology, vol. 148, no. 1, pp. 89–93, 1996.
  104. D M Moraga, P Nunez, J Garrido, and R B Maccioni, “A tau fragment containing a repetitive sequence induces bundling of actin filaments,” Journal of Neurochemistry, vol. 61, no. 3, pp. 979–986, 1993. View at Publisher · View at Google Scholar
  105. P I Moreira, M A Smith, X Zhu, A Nunomura, R J Castellani, and G Perry, “Oxidative stress and neurodegeneration,” Annals of the New York Academy of Sciences, vol. 1043, pp. 545–552, 2005. View at Publisher · View at Google Scholar
  106. L Nanetti, A Vignini, C Moroni, et al., “Peroxynitrite production and NOS expression in astrocytes U373MG incubated with lipoproteins from Alzheimer patients,” Brain Research, vol. 1054, no. 1, pp. 38–44, 2005. View at Publisher · View at Google Scholar
  107. T J Nelson and D L Alkon, “Oxidation of cholesterol by amyloid precursor protein and β-amyloid peptide,” Journal of Biological Chemistry, vol. 280, no. 8, pp. 7377–7387, 2005. View at Publisher · View at Google Scholar
  108. M R Nicolls, “The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease,” Current Alzheimer Research, vol. 1, no. 1, pp. 47–54, 2004. View at Publisher · View at Google Scholar
  109. R A Nixon, “Niemann-Pick type C disease and Alzheimer's disease: the APP-endosome connection fattens up,” American Journal of Pathology, vol. 164, no. 3, pp. 757–761, 2004.
  110. J M Olson, K AB Goddard, and D M Dudek, “A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the Amyloid Precursor Protein region,” American Journal of Human Genetics, vol. 71, no. 1, pp. 154–161, 2002. View at Publisher · View at Google Scholar
  111. D I Orellana, R A Quintanilla, C Gonzalez-Billault, and R B Maccioni, “Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons,” Neurotoxicity Research, vol. 8, no. 3-4, pp. 295–304, 2005.
  112. A Ott, M MB Breteler, M C De Bruyne, F van Harskamp, D E Grobbee, and A Hofman, “Atrial fibrillation and dementia in a population-based study: the Rotterdam study,” Stroke, vol. 28, no. 2, pp. 316–321, 1997.
  113. C Otth, I I Concha, T Arendt, et al., “AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576,” Journal of Alzheimer's Disease, vol. 4, no. 5, pp. 417–430, 2002.
  114. K Pahan, F G Sheikh, M S Namboodiri, and I Singh, “Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages,” Journal of Clinical Investigation, vol. 100, no. 11, pp. 2671–2679, 1997.
  115. R Pankov, T Markovska, R Hazarosova, P Antonov, L Ivanova, and A Momchilova, “Cholesterol distribution in plasma membranes of β1 integrin-expressing and β1 integrin-deficient fibroblasts,” Archives of Biochemistry and Biophysics, vol. 442, no. 2, pp. 160–168, 2005. View at Publisher · View at Google Scholar
  116. A Papassotiropoulos, D Lütjohann, M Bagli, et al., “Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease,” NeuroReport, vol. 11, no. 9, pp. 1959–1961, 2000. View at Publisher · View at Google Scholar
  117. A Papassotiropoulos, M A Wollmer, M Tsolaki, et al., “A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease,” Journal of Clinical Psychiatry, vol. 66, no. 7, pp. 940–947, 2005.
  118. M A Pappolla, T K Bryant-Thomas, D Herbert, et al., “Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology,” Neurology, vol. 61, no. 2, pp. 199–205, 2003.
  119. I-H Park, E M Hwang, H S Hong, et al., “Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice,” Neurobiology of Aging, vol. 24, no. 5, pp. 637–643, 2003. View at Publisher · View at Google Scholar
  120. I-H Park, E M Hwang, H S Hong, et al., “Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice,” Neurobiology of Aging, vol. 24, no. 5, pp. 637–643, 2003. View at Publisher · View at Google Scholar
  121. L J Pike, “Lipid rafts: heterogeneity on the high seas,” Biochemical Journal, vol. 378, no. 2, pp. 281–292, 2004. View at Publisher · View at Google Scholar
  122. D Potyk, “Treatments for Alzheimer disease,” Southern Medical Journal, vol. 98, no. 6, pp. 628–635, 2005. View at Publisher · View at Google Scholar
  123. A Pralle, P Keller, E-L Florin, K Simons, and J KH Hörber, “Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells,” Journal of Cell Biology, vol. 148, no. 5, pp. 997–1008, 2000. View at Publisher · View at Google Scholar
  124. L Puglielli, A L Friedlich, K DR Setchell, et al., “Alzheimer disease β-amyloid activity mimics cholesterol oxidase,” Journal of Clinical Investigation, vol. 115, no. 9, pp. 2556–2563, 2005. View at Publisher · View at Google Scholar
  125. R A Quintanilla, D I Orellana, C González-Billault, and R B Maccioni, “Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway,” Experimental Cell Research, vol. 295, no. 1, pp. 245–257, 2004. View at Publisher · View at Google Scholar
  126. H Rafael, “Cerebral atherosclerosis and oxidative stress in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 5, no. 6, pp. 479–480, 2003.
  127. L Rajendran and K Simons, “Lipid rafts and membrane dynamics,” Journal of Cell Science, vol. 118, no. 6, pp. 1099–1102, 2005. View at Publisher · View at Google Scholar
  128. E T Saez, M Pehar, M Vargas, L Barbeito, and R B Maccioni, “Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons,” In Vivo, vol. 18, no. 3, pp. 275–280, 2004.
  129. Y Saito and S Murayama, “Expression of tau immunoreactivity in the spinal motor neurons of Alzheimer's disease,” Neurology, vol. 55, no. 11, pp. 1727–1729, 2000.
  130. S C Samuels and H Grossman, “Emerging therapeutics for Alzheimer's disease: an avenue of hope,” CNS Spectrums, vol. 8, no. 11, pp. 834–845, 2003.
  131. L M Sayre, D A Zelasko, P LR Harris, G Perry, R G Salomon, and M A Smith, “4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997.
  132. L M Sayre, D A Zelasko, P LR Harris, G Perry, R G Salomon, and M A Smith, “4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997.
  133. P Schönknecht, D Lütjohann, J Pantel, et al., “Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls,” Neuroscience Letters, vol. 324, no. 1, pp. 83–85, 2002. View at Publisher · View at Google Scholar
  134. P Schwille and U Kettling, “Analyzing single protein molecules using optical methods,” Current Opinion in Biotechnology, vol. 12, no. 4, pp. 382–386, 2001. View at Publisher · View at Google Scholar
  135. D J Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. View at Publisher · View at Google Scholar
  136. M L Selley, D R Close, and S E Stern, “The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease,” Neurobiology of Aging, vol. 23, no. 3, pp. 383–388, 2002. View at Publisher · View at Google Scholar
  137. S Seshadri, A Beiser, J Selhub, et al., “Plasma homocysteine as a risk factor for dementia and Alzheimer's disease,” New England Journal of Medicine, vol. 346, no. 7, pp. 476–483, 2002. View at Publisher · View at Google Scholar
  138. T B Shea, “Phospholipids alter tau conformation, phosphorylation, proteolysis, and association with microtubules: implication for tau function under normal and degenerative conditions,” Journal of Neuroscience Research, vol. 50, no. 1, pp. 114–122, 1997. View at Publisher · View at Google Scholar
  139. J Shepherd, G J Blauw, M B Murphy, et al., “Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial,” Lancet, vol. 360, no. 9346, pp. 1623–1630, 2002. View at Publisher · View at Google Scholar
  140. D K Simon, M T Lin, L Zheng, et al., “Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease,” Neurobiology of Aging, vol. 25, no. 1, pp. 71–81, 2004. View at Publisher · View at Google Scholar
  141. K Simons and E Ikonen, “Functional rafts in cell membranes,” Nature, vol. 387, no. 6633, pp. 569–572, 1997. View at Publisher · View at Google Scholar
  142. A J Sinclair, A J Bayer, J O Johnston, C Warner, and S RJ Maxwell, “Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia,” International Journal of Geriatric Psychiatry, vol. 13, no. 12, pp. 840–845, 1998. View at Publisher · View at Google Scholar
  143. M Sjögren and K Blennow, “The link between cholesterol and Alzheimer's disease,” World Journal of Biological Psychiatry, vol. 6, no. 2, pp. 85–97, 2005. View at Publisher · View at Google Scholar
  144. M Sjögren, K Gustafsson, S Syversen, et al., “Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved amyloid precursor protein,” Dementia and Geriatric Cognitive Disorders, vol. 16, no. 1, pp. 25–30, 2003. View at Publisher · View at Google Scholar
  145. I Skoog, “Hypertension and cognition,” International Psychogeriatrics, vol. 15, no. suppl 1, pp. 139–146, 2003. View at Publisher · View at Google Scholar
  146. I Skoog, B Lernfelt, S Landahl, et al., “15-year longitudinal study of blood pressure and dementia,” Lancet, vol. 347, no. 9009, pp. 1141–1145, 1996. View at Publisher · View at Google Scholar
  147. D L Sparks, M N Sabbagh, D J Connor, et al., “Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results,” Archives of Neurology, vol. 62, no. 5, pp. 753–757, 2005. View at Publisher · View at Google Scholar
  148. K Stamer, R Vogel, E Thies, E Mandelkow, and E-M Mandelkow, “Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress,” Journal of Cell Biology, vol. 156, no. 6, pp. 1051–1063, 2002. View at Publisher · View at Google Scholar
  149. F Stellaard and F Kuipers, “Assessment of modes of action and efficacy of plasma cholesterol-lowering drugs: measurement of cholesterol absorption, cholesterol synthesis and bile acid synthesis and turnover using novel stable isotope techniques,” Current Drug Targets: Immune, Endocrine and Metabolic Disorders, vol. 5, no. 2, pp. 209–218, 2005. View at Publisher · View at Google Scholar
  150. S A Tatulian, S Qin, A H Pande, and X He, “Positioning membrane proteins by novel protein engineering and biophysical approaches,” Journal of Molecular Biology, vol. 351, no. 5, pp. 939–947, 2005. View at Publisher · View at Google Scholar
  151. R D Terry, E Masliah, D P Salmon, et al., “Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment,” Annals of Neurology, vol. 30, no. 4, pp. 572–580, 1991. View at Publisher · View at Google Scholar
  152. K M Thelen, K M Rentsch, U Gutteck, et al., “Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 1146–1152, 2006. View at Publisher · View at Google Scholar
  153. S Treiber-Held, R Distl, V Meske, F Albert, and T G Ohm, “Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease,” Journal of Pathology, vol. 200, no. 1, pp. 95–103, 2003. View at Publisher · View at Google Scholar
  154. H Tun, L Marlow, I Pinnix, R Kinsey, and K Sambamurti, “Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway,” Journal of Molecular Neuroscience, vol. 19, no. 1-2, pp. 31–35, 2002.
  155. K Uchida, M Kanematsu, Y Morimitsu, T Osawa, N Noguchi, and E Niki, “Acrolein is a product of lipid peroxidation reaction: formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins,” Journal of Biological Chemistry, vol. 273, no. 26, pp. 16058–16066, 1998. View at Publisher · View at Google Scholar
  156. M T Vanier and K Suzuki, “Recent advances in elucidating Niemann-Pick C disease,” Brain Pathology, vol. 8, no. 1, pp. 163–174, 1998.
  157. G L Vega, M Weiner, H Kölsch, et al., “The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins,” Current Alzheimer Research, vol. 1, no. 1, pp. 71–77, 2004. View at Publisher · View at Google Scholar
  158. G L Vega, M F Weiner, A M Lipton, et al., “Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease,” Archives of Neurology, vol. 60, no. 4, pp. 510–515, 2003. View at Publisher · View at Google Scholar
  159. E Von Strauss, M Viitanen, D De Ronchi, B Winblad, and L Fratiglioni, “Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians,” Archives of Neurology, vol. 56, no. 5, pp. 587–592, 1999. View at Publisher · View at Google Scholar
  160. S Wada, M Morishima-Kawashima, Y Qi, et al., “γ-secretase activity is present in rafts but is not cholesterol-dependent,” Biochemistry, vol. 42, no. 47, pp. 13977–13986, 2003. View at Publisher · View at Google Scholar
  161. S Wahrle, P Das, A C Nyborg, et al., “Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains,” Neurobiology of Disease, vol. 9, no. 1, pp. 11–23, 2002. View at Publisher · View at Google Scholar
  162. K A Wesnes, I G McKeith, R Ferrara, et al., “Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system,” Dementia and Geriatric Cognitive Disorders, vol. 13, no. 3, pp. 183–192, 2002. View at Publisher · View at Google Scholar
  163. C M Wischik and R A Crowther, “Subunit structure of the Alzheimer tangle,” British Medical Bulletin, vol. 42, no. 1, pp. 51–56, 1986.
  164. B Wolozin, W Kellman, P Ruosseau, G G Celesia, and G Siegel, “Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors,” Archives of Neurology, vol. 57, no. 10, pp. 1439–1443, 2000. View at Publisher · View at Google Scholar
  165. P J Yao, M Zhu, E I Pyun, et al., “Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease,” Neurobiology of Disease, vol. 12, no. 2, pp. 97–109, 2003. View at Publisher · View at Google Scholar
  166. C A Zambrano, J T Egaña, M T Núñez, R B Maccioni, and C González-Billault, “Oxidative stress promotes τ dephosphorylation in neuronal cells: the roles of cdk5 and PP1,” Free Radical Biology and Medicine, vol. 36, no. 11, pp. 1393–1402, 2004. View at Publisher · View at Google Scholar
  167. M Zappia, I Manna, P Serra, et al., “Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms,” Archives of Neurology, vol. 61, no. 3, pp. 341–344, 2004. View at Publisher · View at Google Scholar
  168. F L Zhang and P J Casey, “Protein prenylation: molecular mechanisms and functional consequences,” Annual Review of Biochemistry, vol. 65, pp. 241–269, 1996. View at Publisher · View at Google Scholar
  169. G S Zubenko, H B III Hughes, and J S Stiffler, “D10S1423 identifies a susceptibility locus for Alzheimer's disease in a prospective, longitudinal, double-blind study of asymptomatic individuals,” Molecular Psychiatry, vol. 6, no. 4, pp. 413–419, 2001. View at Publisher · View at Google Scholar